![Opinion on medicine for use outside EU: Mosquirix, RTS,S [Portion of P. falciparum circumsporozoite protein fused with hepatitis B surface antigen (RTS), and combined with hepatitis B surface antigen (S)], Malaria, 23/07/2015 Positive opinion](https://www.ema.europa.eu/sites/default/files/styles/oe_bootstrap_theme_medium_no_crop/public/2024-07/EMA_building_202407_v1-copyright-EMA.png?itok=NBYia_Eu)
Finland’s Marimekko’s Q1 sales hit $42.9 mn, eyes expansion in Asia
Marimekko is expecting increased net sales and a 16–19 per cent operating profit margin in 2025, with strong growth projected in the Asia-Pacific region. The company plans 10–15 new store openings, mainly in Asia. Q1 2025 net sales rose 5 per cent to €39.6 million, driven by international growth. CEO Alahuhta-Kasko highlighted ongoing global expansion, and brand storytelling.
Marimekko is expecting increased net sales and a 16–19 per cent operating profit margin in 2025, with strong growth projected in the Asia-Pacific region.
The company plans 10–15 new store openings, mainly in Asia.
Q1 2025 net sales rose 5 per cent to €39.6 million, driven by international growth.
CEO Alahuhta-Kasko highlighted ongoing global expansion, and brand storytelling.
